

RESEARCH

Open Access



Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA

Min Kang^{1,2,3*}, Bo Tang^{1,4*}, Jixi Li¹, Ziyang Zhou¹, Kang Liu¹, Rensheng Wang³, Ziyang Jiang^{2,5}, Fangfang Bi^{2,6}, David Patrick², Dongin Kim⁷, Anirban K. Mitra^{8,9} and Yang Yang-Hartwich^{2,10*} 

Abstract

Background: Very few proteins encoded by the presumed non-coding RNA transcripts have been identified. Their cellular functions remain largely unknown. This study identifies the tumor-suppressor function of a novel microprotein encoded by the precursor of miR-34a. It consists of 133 amino acid residues, thereby named as miPEP133 (pri-microRNA encoded peptide 133).

Methods: We overexpressed miPEP133 in nasopharyngeal carcinoma (NPC), ovarian cancer and cervical cancer cell lines to determine its effects on cell growth, apoptosis, migration, or invasion. Its impact on tumor growth was evaluated in a xenograft NPC model. Its prognostic value was analyzed using NPC clinical samples. We also conducted western blot, immunoprecipitation, mass spectrometry, confocal microscopy and flow cytometry to determine the underlying mechanisms of miPEP133 function and regulation.

Results: miPEP133 was expressed in normal human colon, stomach, ovary, uterus and pharynx. It was downregulated in cancer cell lines and tumors. miPEP133 overexpression induced apoptosis in cancer cells and inhibited their migration and invasion. miPEP133 inhibited tumor growth in vivo. Low miPEP133 expression was an unfavorable prognostic marker associated with advanced metastatic NPC. Wild-type p53 but not mutant p53 induced miPEP133 expression. miPEP133 enhanced p53 transcriptional activation and miR-34a expression. miPEP133 localized in the mitochondria to interact with mitochondrial heat shock protein 70kD (HSPA9) and prevent HSPA9 from interacting with its binding partners, leading to the decrease of mitochondrial membrane potential and mitochondrial mass.

Conclusion: miPEP133 is a tumor suppressor localized in the mitochondria. It is a potential prognostic marker and therapeutic target for multiple types of cancers.

Keywords: miPEP133, Tumor suppressor, miR-34a, Pri-miRNA-encoded protein, Nasopharyngeal carcinoma

* Correspondence: km1019@163.com; dr_sntangbo@163.com; yang.yang@yale.edu

¹The First Affiliated Hospital of Guangxi Medical University, Nanning 530022, Guangxi, China

²Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Non-coding RNAs (ncRNAs) include long non-coding RNAs (lncRNAs, longer than 200 nucleotides) and small non-coding RNAs (sncRNAs, shorter than 200 nucleotides). MicroRNAs (miRNAs) are small ncRNAs consisting of 20–24 nucleotides that negatively regulate the stability and translational efficiency of target mRNAs through binding to the 3' untranslated regions [1]. Many of them have been demonstrated to play crucial roles in post-transcriptional gene regulation and cancer biology. Genes of miRNAs were assumed to be incapable of encoding proteins. The biogenesis of miRNAs involves the processing of larger primary miRNAs (pri-miRNAs) into shorter pre-miRNAs, and the maturation of pre-miRNA to produce active miRNAs [2]. Recent studies have demonstrated that pri-miRNAs harbor short open reading frames that can encode regulatory peptides, termed miRNA-encoded peptides (miPEPs).

miPEPs that regulate growth and development were first identified in plants. For example, miPEP171b of *Medicago truncatula* and miPEP165a of *Arabidopsis thaliana* are two plant miPEPs that positively regulate the levels of their corresponding miRNAs [3]. The over-expressed miPEPs or synthetic peptides specifically increase the accumulation of the corresponding miRNAs and enhance the inhibition of the miRNA-targeted genes involved in root development. Therefore, it is hypothesized that miPEPs specifically stimulate the transcription of their associated miRNA to induce more pronounced silencing of miRNA-targeted genes. However, it is unclear how miPEPs regulate the transcription machinery. The molecular basis of miPEP specificity and activity are unknown.

In animals, very few miPEPs have been identified till date. Two peptides encoded by lncRNAs were identified as important regulators of muscle physiology [4, 5]. Myoregulin (MLN) is encoded by a skeletal muscle-specific lncRNA. It finely controls calcium uptake by interacting with sarco/endoplasmic reticulum calcium ATPase (SERCA) and plays a critical role in regulating skeletal muscle performance. Another peptide of 34 amino acids named dwarf open reading frame (DWORF) also interacts with SERCA and enhances cardiac muscle contractility. A ncRNA-encoded microprotein named Cancer-Associated Small Integral Membrane Open reading frame 1 (CASIMO1) was recently identified as a 10 kDa protein encoded by a long non-coding RNA (NR_029453). CASIMO1 interacts with squalene epoxidase to regulate lipid droplet clustering and the proliferation of breast cancer cells [6].

miR-34a is a tumor suppressor that inhibits the expression of about 700 target genes [7]. It plays an important role in suppressing tumorigenesis and is downregulated in human cancers [8–10]. The expression

of miR-34a is mainly induced by p53 [11–13]. However, accumulating evidence indicates that the level of miR-34a can be regulated in a p53-independent manner. Due to its anti-cancer functions, miR-34a has become one of the first targets of miRNA therapy entering clinical trials [14, 15].

In this study, we report for the first time the identification and functional characterization of a miPEP encoded by the primary transcript of miR-34a. We named it miPEP133 (pri-miR encoded peptide 133) because it consists of 133 amino acid residues. Since miPEP133 is highly expressed in the normal pharynx and significantly downregulated in nasopharyngeal carcinoma (NPC), we utilized the in vitro and in vivo models of NPC to study the role of miPEP133 in tumorigenesis. NPC is a rare type of head and neck cancer with 80,000 incident cases and 50,000 deaths annually [16]. It is more prevalent in southern China, southeastern Asian countries, northern and northeastern Africa, Alaska, and western Canada [17]. NPC is a leading cancer type in Malaysia [18]. NPC is usually sensitive to radiotherapy. If diagnosed at early stage it is considered curable with the 5-year survival rate of about 80% [19]. However, more than 30% of patients will relapse with local recurrence or distant metastases [20]. When NPC progresses into advanced disease, the prognosis is very poor. The clinical management of late stage NPC is extremely challenging. Research on the tumor biology and etiology of NPC is very limited comparing to other more common cancer types. Our findings on the regulation and functions of miPEP133 will advance our knowledge on the roles of miPEPs in tumorigenesis and tumor progression.

Methods

Human tissue samples

The NPC study protocol was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. The procedures are in accordance with the Helsinki Declaration of 1975. Written informed consent was obtained from all participants. Normal nasopharyngeal tissues adjacent to the operation areas were collected from 8 patients. Ovarian cancer sample collection was carried out with patient consent and approved by the Human Investigations Committee of Yale University School of Medicine. Tissue samples were immediately frozen in liquid nitrogen after resection and stored at -80°C until use. Clinical information regarding the tissue samples is in Additional file 1.

Cell lines and transfection

Human NPC cell lines HNE3, C666–1, CNE2, CNE1, 5–8F, TWO3, and normal nasopharyngeal cell line NP69 were gifts from Guangxi Medical University Nasopharyngeal Cancer Research Laboratory. SKOV3 and HeLa

cell lines were obtained from NCI Repository of Tumors and Tumor Cell Lines. The ovarian cancer patient-derived cell lines were provided by Dr. Gil Mor (Yale University). Fallopian tube epithelial cell lines were generated previously [21] and provided by Dr. Ron Drapkin (University of Pennsylvania). Cells were cultured in DMEM containing 10% fetal bovine serum, 100 IU/ml penicillin and 100 mg/ml streptomycin in humidified 5% CO₂ incubator at 37 °C. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used for transfection according to the manufacturer's instruction. Lentivirus was produced as previously described to establish stable cell lines with miPEP133 overexpression [22]. Puromycin (1 µg/ml, Invitrogen) was used to maintain selective pressure. Details about plasmids used in this study are listed in Additional file 2.

Antibody production and evaluation

The production of anti-miPEP133 antibody was conducted by GenScript (Piscataway, NJ, USA) as described in Additional file 2. The antibody was evaluated by SDS-PAGE and Coomassie Brilliant Blue staining. The specificity of the produced antibody against miPEP133 was validated by ELISA.

Western blot and co-immunoprecipitation (co-IP)

Details of western blot and co-IP and the information of antibodies are described in Additional file 2.

Quantitative PCR (QPCR)

Total RNA was extracted using TRIzol reagent (Invitrogen) and reverse-transcribed using Bulge-Loop™ microRNA specific RTprimers (RiboBio, Guangzhou, China) and M-MLV reverse transcriptase (Promega, Madison, WI, USA). Real-time QPCR was performed on a CFX96Touch™ system (Bio-Rad, Hercules, CA, USA) using SYBR SuperMix (Bio-Rad). Mir-X miRNA qRT-PCR TB Green Kit (Takara Bio, San Francisco, CA) was used to detect miR-34a. RNU6B (U6) or GAPDH were used as internal controls. Relative expression levels were calculated using the $2^{-\Delta\Delta CT}$ method. Primers are listed in Additional file 2.

Mass spectrometry

The gel piece containing the 15 kDa protein band from HEK293 cell lysate was excised and digested into peptide fragments for mass spectrometry analysis. Mass spectrometry was performed as previously described [23]. For the identification of miPEP133-binding proteins, the protein lysate of HEK293 cells expressing flag-labeled miPEP133 or control empty vector was incubated with anti-flag-tag antibody in the co-IP assay. Proteins in the co-IP products were identified by mass spectrometry analysis. The proteins that were identified in the IP

product of cells transfected with empty vector were excluded from the list of protein hits as background signals (Additional file 4).

miPEP133 knockdown with siRNAs and CRISPR/Cas9-mediated miPEP133 deletion

siRNAs were transfected using Lipofectamine RNAi-MAX (Invitrogen) following the manufacturer's instruction. miPEP133 siRNAs were synthesized by Ribo Biotechnology (Guangzhou, China). The sequences of siRNAs and the method of CRISPR/Cas9-mediated miPEP133 deletion are listed in Additional file 2.

Cell fractionation and RNA/protein extraction

The cytoplasmic and nuclear RNA was extracted from cells using Cytoplasmic and Nuclear RNA Purification kit (Norgen BioTeck, Thorold, ON, Canada). Cell fractionation and protein extraction were performed using Qproteome Mitochondria Isolation kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instruction.

Cell proliferation assay

Five thousand cells/well were plated in 96-well plates. Cell viability reagent WST-8 (Abcam, Branford, CT) was added to each well and incubated for 3 h at 37 °C at different time points. Optical density at 450 nm was measured using plate reader.

Flow cytometry analysis of apoptosis, cell cycle, and mitochondrial membrane potential

Cells were stained according to the instruction of the Annexin V-APC/7-AAD kit (Keygen Biotech, Nanjing, China) and analyzed using FACSLytic Flow cytometry system (BD, Franklin Lakes, NJ) to assess the apoptotic cell populations. Cell cycle status was analyzed by propidium bromide (PI) staining and flow cytometry as detailed in Additional file 2. JC-1 mitochondrial membrane potential assay kit (abcam) was used to stain the cells and assess mitochondrial membrane potential by flow cytometer. A potent mitochondrial uncoupler, carbonyl cyanide chlorophenylhydrazone (CCCP) was used as a positive control.

Migration assay and invasion assay

For wound healing assay, cells were seeded in 6-well plates, grown to 90% confluence. A scratch wound was made using a pipet tip. Wound width was measured under microscope at 24 h. For the transwell migration assay, cells were seeded into the transwells directly (Corning, Corning, NY, USA) with 0.2 mL serum-free medium. For the invasion assay, cells were seeded into the Matrigel-coated transwells (Corning). The bottom wells were filled with normal growth medium. After 24 h, cells in the upper wells were removed using a cotton swab. The migrating/invading cells at the bottom of the

transwells were fixed in 4% polyoxymethylene, stained with crystal violet, and imaged in randomly chosen fields. The stained cells were counted.

p53 response element luciferase reporter assay

PG13-luc (wt p53 binding sites) was a gift from Bert Vogelstein (Addgene plasmid # 16442; <http://n2t.net/addgene:16442>; RRID:Addgene_16,442). Renilla luciferase control reporter pRL vector was purchased from Promega (Madison, WI, USA). miPEP-133 or control vector was co-transfected with PG13-luc plasmid. p53 transcriptional activation was evaluated as previously described [24].

Immunofluorescence (IF) staining and confocal microscopy

Formalin-fixed paraffin-embedded tissue sections were deparaffinized and hydrated. Slides were submerged in 1X citrate unmasking solution and heated in a microwave to incubate at 95–98 °C for 10 min. Cells were cultured on chamber slides, fixed with 4% paraformaldehyde in PBS for 10 min at room temperature, and then washed with PBS. The slides were incubated in blocking buffer (5% normal serum and 0.3% Triton X-100 in PBS) for 60 min at room temperature. Primary antibodies were diluted in antibody dilution buffer (1% BSA and 0.3% Triton X-100 in 1X PBS) and incubated with the slides overnight at 4 °C. Fluorochrome-conjugated secondary antibody was incubated for 1 h at room temperature in the dark. Mount medium with DAPI was used to mount the slides (Cell Signaling, Danvers, MA, USA). The stained slides were imaged using Leica SP8 Laser Scanning Confocal microscope. Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) staining was performed using In Situ Cell Death Detection kit (Roche, Branford, CT, USA).

Luminescence-based ATP detection assay

Cells were counted using a hemocytometer. Cell suspension was mixed with the same volume of ATP assay reagent (Promega) to incubate for 10 min. The luminescent signal was measured using GloMax Navigator plate reader (Promega).

Mouse model

Six-week-old female BALB/c-nude mice (Shanghai Laboratory Animal, Shanghai, China) were subcutaneously injected with 10^7 C666–1 cells that expressed miPEP133 or control lentivirus vector. Tumor width (W) and length (L) were measured daily. Tumor volume was calculated using formula $V = \pi/6 * L * W^2$. Three weeks after injection, mice were euthanized to collect the tumors.

Statistics

Data were presented as the mean \pm standard deviation. All experiments included at least 3 biological repeats.

Student's t-test, two-way ANOVA or chi-square test was used in statistical analysis as specified for each experiment. Kaplan–Meier analysis was employed for the survival analysis of two groups (miPEP133 low and high groups). Survival was defined as time from diagnosis until death or until time last followed. The differences in the survival probabilities were estimated using the log-rank test. *P* values less than 0.05 were considered to be statistically significant.


Result

miPEP133 is a microprotein encoded by an ORF in the pri-miRNA of miR-34a

miR-34a is encoded by MIR34AHG gene in the distal region of chromosome 1p. We identified a 402 bp ORF adjacent to the MIR34A precursor sequence region (Fig. 1a). We cloned the ORF into a plasmid vector and transfected HEK293 cells. Using SDS-PAGE and Coomassie blue staining, we detected a band at 15 kDa that was enriched in the ORF-overexpressing cells compared to the control cells (Fig. 1b). We excised the 15 kDa band and digested the proteins into peptides for mass spectrometry analysis. Mass spectrometry analysis confirmed the presence of 4 peptides that matched partial sequences of the ORF protein product (Fig. 1c). This result demonstrates that a 15 kDa protein as the product of this ORF could be stably expressed in cells. We named this protein product as pri-microRNA encodes peptide 133 (miPEP133) since it consists of 133 amino acid residues.

We selected a fragment of miPEP133 (PGPGGTSR KEDPAA) to generate the synthetic peptide-carrier protein conjugate for raising a polyclonal rabbit antibody against miPEP133. Using this antibody in western blot, we detected a 15 kDa band in the cell lysate of HEK293 cells, which intensity was significantly increased in the miPEP133-overexpressing cells (Fig. 1d). We also detected a lower band in the lysate of the miPEP133-overexpressing cells. We postulate that the lower band represents a truncated form of miPEP133 that is cleaved by protease. The overexpression of miPEP133 was also confirmed at RNA level (Fig. 1e).

To verify the specificity of the anti-miPEP133 antibody, we designed three small interfering RNAs (siRNAs) to knock down the endogenous expression of miPEP133 in HEK293 cells. Results of western blot and RT-QPCR showed that two of the siRNAs (#1 and #3) effectively inhibited miPEP133 mRNA expression and significantly decreased the intensity of the 15 kDa protein band that was detected by the anti-miPEP133 antibody (Fig. 1f and g). We also generated two CRISPR/Cas9-mediated deletions of miPEP133, MUT1 and MUT2. They lacked 28 bp and 5 bp in the ORF of miPEP133, respectively (Fig. 1h and Additional file 3: Fig. S1), leading to the loss of the 15 kDa protein band in



HEK293 cells (Fig. 1i). These results validated that the 15 kDa protein detected by this antibody was indeed miPEP133. miPEP133 is naturally expressed by HEK293 cells. Cellular fractionation of RNA showed that miPEP133 mRNA mainly localized in the cytoplasm of HEK293 cells (Fig. 1j).

miPEP133 is expressed in human tissues

Next we assessed the expression of this newly identified protein in different human tissues. Western blot of human tissue homogenates demonstrated that miPEP133 was highly expressed in human colon, ovary, stomach, uterus, and pharynx tissues (Fig. 1k). Similar expression pattern was observed in mouse tissues (Additional file 3: Fig. S2).

NP69 is a normal nasopharyngeal epithelial cell line derived from human pharynx tissue. It is non-tumorigenic and exhibits anchorage-dependent growth. NP69 cells expressed miPEP133 mRNA that mainly localized in the cytoplasm (Fig. 2a). Six nasopharyngeal

cancer cell lines, HNE3, C666–1, CNE2, CNE1, 5-8F and TWO3 showed significantly reduced levels of miPEP133 protein comparing to NP69 (Fig. 2b and c). In NPC samples we also detected significantly lower levels of miPEP133 mRNA than normal nasopharyngeal tissues (Fig. 2d). These findings led us to hypothesize that miPEP133 was a nasopharyngeal endogenous peptide that was downregulated during malignant transformation, possibly playing a role as a tumor suppressor.

miPEP133 is a tumor suppressor that inhibits cancer cell proliferation, migration and invasion

To determine whether miPEP133 acts as a tumor suppressor, we overexpressed miPEP133 in three NPC cell lines (Fig. 2e and f). miPEP133 overexpression inhibited the proliferation of NPC cell lines (Fig. 2g), increased the apoptotic cell populations as assessed by AnnexinV and 7-aminoactinomycin D (7-AAD) staining assay (Fig. 2h and





Fig. 2 Tumor suppressor functions of miPEP133 in nasopharyngeal carcinoma (NPC) cells. **a** RT-QPCR of miPEP133 mRNA in the nuclear and cytoplasmic fractions of NP69 cells. U6 and GAPDH were used as control genes. **b** Representative images of miPEP133 western blot in NP69 and NPC cell lines. **c** Quantification of miPEP133 band intensity in western blot. Student's t-test, $^{**}p < 0.005$. **d** RT-QPCR of miPEP133 in normal pharynx and NPC samples ($n = 8$). Student's t-test, $^{*}p < 0.05$. **e** Western blot of miPEP133 in three NPC cell lines transfected with control (-) or miPEP133 plasmid (+). **f** Quantification of miPEP133 band intensity in western blot. Student's t-test, $^{**}p < 0.005$. **g** Cell growth rates of NPC cell lines. Two-way ANOVA followed by Sidak's test, $^{*}p < 0.05$, $^{**}p < 0.005$, $^{***}p < 0.001$, $^{\#}p < 0.0001$. **h** Flow cytometry dot plots of C666-1 cells stained with AnnexinV/7-ADD. **i** Summarized flow cytometry results of AnnexinV/7-ADD-staining in NPC cell lines. Student's t-test, $^{*}p < 0.05$. **j** Cell cycle status of C666-1 cells determined by PI staining and flow cytometry. **k** Summarized flow cytometry results of PI-staining in three NPC cell lines. Student's t-test, $^{*}p < 0.05$. **l** Representative images of wound healing assay at 0 h and 24 h of control C666-1 cells and the miPEP133-overexpressing C666-1 cells. **m** Quantification of wound closure of control C666-1 cells and the miPEP133-overexpressing C666-1 cells at 24 h. Wound closure was presented as the percentage of wound width that was closed. Student's t-test, $^{\#}p < 0.0001$. **n** Representative images of migrating cells in trans-well assay. **o** Quantification of migrating cells in the transwell migration assay. Student's t-test, $^{\#}p < 0.0001$. **p** Representative images of invading cells in trans-well assay. **q** Quantification of invading cells in the transwell invasion assay. Student's t-test, $^{\#}p < 0.0001$

i), and induced cell cycle arrest at G1 phase (Fig. 2j and k). In scratch wound healing assays, the migration of C666-1 cells that overexpressed miPEP133 was significantly slower than the control C666-1 cells (Fig. 2l and m). In transwell migration assays, fewer cells migrated in the miPEP133-overexpressing group than the control group (Fig. 2n and o). In transwell invasion assays, the numbers of C666-1 cells that invaded through the Matrigel were significantly reduced in the miPEP133-overexpressing group than the control group (Fig. 2p and q).

miPEP133 inhibits tumor growth in vivo

We next demonstrated the role of miPEP133 as a tumor suppressor in a xenograft NPC model in vivo. C666-1 cells were subcutaneously injected into the flank of nude mice. The tumor growth of miPEP133-overexpressing C666-1 cells was significantly suppressed when compared to that of the control C666-1 cells (Fig. 3a). Three weeks after the inoculation, tumors collected from the miPEP133-overexpressing group were significantly smaller than those in the control group (Fig. 3b and



Additional file 3: Fig. S3). We confirmed the stable over-expression of miPEP133 in the tumor tissues at protein and RNA levels (Fig. 3c and d). Importantly, we identified the upregulation of miR-34a in the tumors over-expressing miPEP133, suggesting that miPEP133 induced the expression of miR-34a (Fig. 3e).

The immunofluorescence (IF) staining of tumor tissues demonstrated that the miPEP133-overexpressing tumors had lower percentages of Ki67-positive proliferating cells, higher percentages of TUNEL positive apoptotic cells, and higher percentages of cleaved-caspase-3-positive apoptotic cells than the control tumors (Fig. 3f, g, h,

and i). This result again supports the role of miPEP133 in inhibiting proliferation and inducing apoptosis in cancer cells.

miPEP133 is a prognostic marker that is downregulated in recurrent and advanced NPC

We evaluated the expression levels of miPEP133 by RT-QPCR and analyzed their relation to clinical characteristics in 85 cases of NPC. No significant association between miPEP expression level and sex, age, smoking history, T staging, N staging, or TNM staging was observed (Additional file 1). The average level of miPEP133

mRNA was higher in stage I/II NPC than that of stage III or stage IV, and stage III NPC expressed higher levels of miPEP133 mRNA than stage IV NPC (Fig. 3j). The down-regulation of miPEP133 mRNA was associated with tumor recurrence (Fig. 3k) and metastatic diseases (Fig. 3l). We divided the cases into miPEP133-high and miPEP133-low groups using the mean of miPEP133 mRNA level as a cut-off. The Kaplan-Meier survival analysis and Log-rank test result suggests that the miPEP133-low group had a significantly lower overall survival rate than the miPEP133-high group ($p = 0.014$, Fig. 3m). These results indicate that the downregulation of miPEP133 is a potential prognostic marker for poor clinical outcomes and advanced diseases.

miPEP133 interacts with mitochondrial heat shock protein 70 (HSPA9) to regulate mitochondrial function

In order to better understand the cellular functions of miPEP133, we performed immunoprecipitation (IP) of miPEP133 in HEK293 cells and analyzed the IP product by mass spectrometry. We identified 18 proteins as miPEP133 binding partners, the majority of which are membrane or cytoplasmic proteins (Fig. 4a and Additional file 4). We confirmed the cytoplasmic localization of miPEP133 in HEK293 and C666-1 cells by transfecting HEK293 and C666-1 cells with a plasmid containing miPEP133 fused with flag-tag and detecting the flag-tagged miPEP133 by IF staining (Fig. 4b).

When we analyzed different cellular protein fractions of HEK293 cells, we identified that miPEP133 was predominantly expressed in the mitochondrial fraction and expressed at a much lower level in the cytoplasmic fraction (Fig. 4c). It was noted that one of the partner proteins identified through mass spectrometry analysis, HSPA9 (also named mtHsp70, GRP75, or Mortalin) was also predominantly present in the mitochondrial fraction (Fig. 4c). Using the mitochondrial fraction as input, we performed co-IP of miPEP133 and HSPA9 and confirmed their direct interaction in the mitochondria (Fig. 4c).

HSPA9 modulates the morphology and function of mitochondria [25–27]. We hypothesize that through the interaction with HSPA9 miPEP133 impacts the functions HSPA9 to regulate mitochondrial morphology and function. Indeed, the overexpression of miPEP133 in HEK293 cells significantly decreased the interaction between HSPA9 and its binding partners, HSP60, TIM44 and VDAC1 (Fig. 4d). miPEP133 overexpression also caused the downregulation of mitochondrial proteins, including translocase of outer mitochondrial membrane 20 (TOM20) and the mitochondrial fission/fusion proteins, DRP1, MFN1, and OPA1 (Fig. 4e). The miPEP133-overexpressing cells showed decreased levels of JC-1 staining than the control cells demonstrating a reduction of mitochondrial membrane potential (Fig. 4f). IF staining of TOM20 in the miPEP133-overexpressing cells


confirmed the decreased levels of TOM20 expression and revealed more fragmented mitochondria and more shrinking nuclei in the miPEP133-overexpressing cells than the control cells (Fig. 4g). miPEP133-overexpressing cells produced significantly lower levels of ATP than the same numbers of control cells (Fig. 4h). As previously reported, the inhibition of HSPA9 leads to mitochondrial proteolytic stress, mitochondrial fragmentation, reduced mitochondrial mass, and increased apoptosis [26, 28]. Therefore, our findings demonstrate that miPEP133 binds to HSPA9 to prevent HSPA9 from interacting with HSP60, TIM44 and VDAC1, and inhibits the normal function of HSPA9 as a mitochondrial chaperon, which partially accounts for the miPEP133-induced loss of mitochondrial mass, reduction of mitochondrial membrane potential and ATP production, cell cycle arrest and apoptosis (as illustrated in Fig. 4i).

miPEP133 is transcriptionally regulated by wild-type p53, but not mutant p53

The expression of miR-34a is regulated by p53 through the regions proximal to MIR34AHG gene promoter that contain multiple canonical p53 binding motifs [11, 12]. Since the ORF of miPEP133 is adjacent to miR-34 precursor as part of miR-34a pri-miRNAs (Fig. 1a), we hypothesized that the expression of miPEP133 was also regulated by p53 through MIR34AHG promoter. To test this hypothesis, we first activated p53 with a small-molecule MDM2 antagonist, nutlin-3a, to assess its impact on miPEP133 expression. Our results showed that nutlin-3a treatment for 24 h increased the protein levels of p53 and miPEP133 in HEK293 cells (Fig. 5a and 5b). In addition, miR-34a and miPEP133 mRNA were both upregulated by nutlin-3a treatment (Fig. 5c). Second, we overexpressed wild-type p53 and three common hotspot mutations of p53 (R175H, R248W, and R273H) in HEK293 cells. The overexpressed wild-type p53 induced the upregulation of miPEP133 protein, but the mutant p53 did not affect the levels of miPEP133 (Fig. 5d). These results suggest that wild-type p53 activates miPEP133 transcription. Mutations can impair the ability of p53 to regulate miPEP133 transcription.

miPEP133 promotes p53 transcriptional activation

The overexpression of miPEP133 in HEK293 cells did not change the level of p53 protein (Fig. 5e, f, and g). However, the overexpression of miPEP133 increased the transcription of miR-34a (Fig. 5h) and the other p53 target genes, including MDM2, P21, PUMA, and FAS, which are involved in cell cycle arrest and apoptosis (Fig. 5i). In a p53 response element reporter assay, we identified that miPEP133 overexpression enhanced the p53 transcriptional activity (Fig. 5j). Taken together (as illustrated in Fig. 6k), miPEP133 is transcriptionally activated by wild-




type p53. Mutations can impair the ability of p53 to induce miPEP133 transcription. miPEP133 in turn enhances p53 transcriptional activity without changing the level of p53 protein. miPEP133 induces the transcription of its associated miRNA, miR-34a.

miPEP133 possesses p53-independent tumor suppressor functions

In order to examine the function of miPEP133 in different cellular contexts, we determined the effect of miPEP133 overexpression in an ovarian cancer cell line SKOV3 that is p53 null and HeLa cell line that is known for having p53 inactivated by human papillomavirus

proteins. In SKOV3 and HeLa cells, the levels of miPEP133 protein were significantly lower than that of HEK293 cells (Fig. 6a). We overexpressed miPEP133 in SKOV3 and HeLa cells as confirmed at protein and RNA levels (Fig. 6b and c). The overexpression of miPEP133 induced the upregulation of miR-34a in SKOV3 and HeLa cells (Fig. 6d), which is consistent with the observation in HEK293 and NPC cells. The overexpression of miPEP133 also significantly decreased the cell viability of SKOV3 and HeLa cells (Fig. 6e) and increased the AnnexinV positive apoptotic cell population (Fig. 6f). The JC-1 staining signals were lower in HeLa cells that overexpressed miPEP133 that the control cells




indicating the reduction of mitochondrial membrane potential (Fig. 6g). These results demonstrated that in the absence of functional wild-type p53 miPEP133 still could act as a tumor suppressor to suppress cancer proliferation, induce apoptosis, and decrease mitochondrial membrane potential. The levels of miPEP133 protein in ovarian cancer line OVCAR8 and four patient-derived epithelial ovarian cancer cell lines (OVC201, OVC203, OVC205 and OVC303) were very low or undetectable, in contrast, two immortalized normal human fallopian tube epithelial cell lines (FT240 and FT246) expressed high levels of miPEP133 protein (Fig. 6h). The fallopian tube epithelial cells have been identified as one of the cell-of-origins for high-grade serous ovarian carcinoma that is the most common type of ovarian cancer. We also confirmed the loss of miPEP133 in eight tumor tissue samples from epithelial ovarian cancer patients (Fig. 6i). These results suggest that miPEP133 is also a tumor suppressor in ovarian cancer.

Discussion

In this study, we have identified a novel microprotein that is encoded by an ORF in the precursor of miR-34a. This microprotein, namely miPEP133, mainly localizes in the mitochondria and plays a role as a tumor suppressor with the activity to induce cell cycle arrest, cell growth inhibition, and apoptosis in cancer cells in addition to slowing down cancer cell migration and invasion. We revealed the mechanisms of its function that involves interacting with mitochondrial chaperon HSP9A and disrupting the interaction of HSP9A with other proteins. Our findings demonstrated the tumor suppressor activity of miPEP133 and its potential value as a prognostic marker and therapeutic target.

miPEPs are more common in plant, but rare in animals. miPEP133 is the first miPEP that is identified in the pri-miRNA of tumor suppressor miRNA in human. It shares the same promoter as its associated miRNA, miR-34a. Therefore, the expression patterns of



miPEP133 are similar to miR-34a. miPEP133 and miR-34a are both downregulated in tumor tissues and both regulated by p53. The other inducers of miR-34a, such as ELK1 and TAp73 [29], may also induce miPEP133 expression, which is yet to be determined in the future studies. The target genes of miR-34a are involved in oncogenic signaling pathways, such as cell proliferation (e.g. cyclins, cyclin-dependent kinases, MYCN, NOTCH1, and MDMX), anti-apoptosis (e.g. BCL2 and SIRT1), cancer stem-like cell properties (e.g. CD44, NANOG, and SOX2), metastasis (e.g. SNAI1 and MET), and immune evasion (e.g. PD-L1). miPEP133 can promote the transcription of miR-34a to enhance the silencing of these miR-34a-targeted genes. We have observed the miPEP133-induced downregulation of ATF3, AXIN2, CDKN1A, DLL1, E2F1, E2F2, FOXP1, JAG1, MYCN, SIRT1, and SOX2, which are miR-34a-targeted genes (data not shown).

The mechanisms underlying miPEP133-induced expression of miR-34a may be explained by different co-existing mechanisms under different cellular contexts. In cells with wild-type functional p53, such as HEK293 cells, miPEP133 can disrupt mitochondrial functions, which activates wild-type p53 transcriptional activity

consequently inducing miR34a expression. In the meantime, the miPEP133-induced mitochondrial dysfunction can activate other transcriptional regulators of miR-34a, such as TAp73, to directly bind to the promoter of miR34a [29, 30]. The latter mechanism may be responsible for the miPEP133-induced upregulation of miR-34a in p53-null cancer cells like ovarian cancer cell line SKOV3 [31] and cancer cells without functional wild-type p53. p53 mutation is very common in ovarian cancer, particularly in high-grade serous ovarian carcinoma. NPC cells usually have wild-type p53, however, NPC is highly associated with Epstein-Bar virus that can inactivate p53 [32]. Cervical cancer HeLa cell line is also known for having p53 inactivated by human papillomavirus proteins [33]. Our findings demonstrated the p53-dependent and p53-independent tumor suppressor roles of miPEP133 in different cellular contexts with diverse p53 status.

HSPA9 is involved in stress response, antigen processing, control of cell proliferation, differentiation and tumorigenesis [34]. HSPA9 has anti-apoptotic and proliferative activities [35, 36]. Increasing levels of HSPA9 permit cells to survive lethal conditions [37–39]. HSPA9 influences the function, dynamics, morphology,

and homeostasis of mitochondria as the only ATPase component of the mitochondrial protein import machinery [35, 40, 41]. Mitochondrial protein precursors are chaperoned by HSPA9 into the mitochondrial matrix with the assistance of co-chaperones [42]. HSPA9 forms a complex with HSP60 and floats freely in the mitochondrial matrix to regulate protein folding [43]. HSPA9 also binds the translocase of the mitochondrial inner and outer membranes [44, 45]. Their complexes control the translocation of precursor proteins and their distribution in the matrix and across the mitochondrial membranes [46–48]. HSPA9-VDAC1 complex modulates voltage-dependent anion-selective channel properties [49]. The interaction with miPEP133 prevents HSPA9 from acting as a chaperon and interacting with its partner proteins, which demonstrates a new mechanism for regulating mitochondrial morphology and function.

Conclusion

We have identified a novel microprotein encoded by the precursor of miR-34a, miPEP133. It is a tumor suppressor that induces apoptosis in cancer cells and inhibits their migration and invasion. Low miPEP133 expression is a prognostic marker of advanced and metastatic NPC. We demonstrated the reciprocal regulation between wild-type p53 and miPEP133. miPEP133 localizes in the mitochondria to prevent HSPA9 from interacting with its binding partners and regulate mitochondrial function. A better understanding of miPEP133 function and regulation will provide a new biomarker and potential therapeutic target for improving the prognosis and treatment of NPC and other cancers. Our work also sets a foundation for understanding the roles of miPEPs in the tumorigenesis of all cancer types.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12943-020-01248-9>.

Additional file 1. Basic clinicopathological characteristics of nasopharyngeal carcinoma patients and ovarian cancer tumor sample information.

Additional file 2. This section describes the details of experimental procedures and materials that are not described in the Method Section, including Supplemental methods and lists of primers, antibodies, and plasmids.

Additional file 3. Description of data: This file includes Supplemental Figures S1-S5

Additional file 4. This Excel file contains 3 sheets. They are the lists of proteins identified in control cells, proteins identified in miPEP133-overexpressing cells, and miPEP133-binding proteins confidently identified by excluding the backgrounds in the control cells.

Abbreviations

miPEP133: Pri-microRNA encoded peptide 133; NPC: Nasopharyngeal carcinoma; HSPA9: Heat Shock Protein Family A Member 9, also known as mitochondrial heat shock protein 70kD; ncRNAs: Non-coding RNAs;

lncRNAs: Long non-coding; snRNAs: Small non-coding RNAs; miRNAs: MicroRNAs; miPEPs: MiRNA-encoded peptides; MLN: Myoregulin; SERCA: Sarco/endoplasmic reticulum calcium ATPase; DWORF: Dwarf open reading frame; CASIMO1: Cancer-Associated Small Integral Membrane Open reading frame 1; co-IP: Co-immunoprecipitation; QPCR: Quantitative PCR; CCCP: Carbonyl cyanide chlorophenylhydrazone; TUNEL: Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling; BSA: Bovine serum albumin; PBS: Phosphate-buffered saline; IF: Immunofluorescence; ATP: Adenosine triphosphate; siRNAs: Small interfering RNAs; CRISPR: Clustered regularly interspaced short palindromic repeats; Cas9: CRISPR-associated protein 9; IP: Immunoprecipitation; HSP60: Heat shock protein 60; TIM44: Translocase Of Inner Mitochondrial Membrane 44; VDAC1: Voltage Dependent Anion Channel 1; TOM20: Translocase of Outer Mitochondrial membrane 20; DRP1: Dynamin-Related Protein 1; MFN1: Mitofusin 1; OPA1: OPA1 Mitochondrial Dynamin Like GTPase; JC-1: 5,5,6,6-Tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbocyanine iodide; MDM2: Mouse double minute 2 homolog; P21: Cyclin Dependent Kinase Inhibitor 1A, encoded by the CDKN1A gene, also known as Cip1; PUMA: p53 upregulated modulator of apoptosis, also known as Bcl-2-binding component 3; FAS: Fas Cell Surface Death Receptor; ELK1: ETS Transcription Factor ELK1; Tap73: Tumor protein p73; NOTCH1: Notch Receptor 1; MDMX: also known as MDM4, Mouse Double Minute 4, Human Homolog Of; P53-Binding Protein; BCL2: BCL2 Apoptosis Regulator; SIRT1: Sirtuin 1; NANOG: Nanog Homeobox; SOX2: SRY-Box Transcription Factor 2; SNAI1: Snail Family Transcriptional Repressor 1; MET: MET Proto-Oncogene, Receptor Tyrosine Kinase; PD-L1: Programmed Cell Death 1 Ligand 1, also known as CD274 Molecule; ATF3: Activating Transcription Factor 3; AXIN2: Axin 2; CDKN1A: Cyclin Dependent Kinase Inhibitor 1A; DLL1: Delta Like Canonical Notch Ligand 1; E2F1: E2F Transcription Factor 1; E2F2: E2F Transcription Factor 2; FOXP1: Forkhead Box P1; JAG1: Jagged Canonical Notch Ligand 1; MYCN: MYCN Proto-Oncogene, BHLH Transcription Factor

Acknowledgements

We thank the Guangxi Medical University Nasopharyngeal Cancer Research Laboratory for providing the nasopharyngeal cell lines, Dr. Gil Mor (Yale University) for providing the ovarian cancer patient-derived cell lines, and Dr. Ron Drapkin (University of Pennsylvania) for providing the fallopian tube epithelial cell lines.

Authors' contributions

M.K. designed experiments, conducted experiments, analyzed data, and drafted the manuscript. B.T., J.L., Z.Z., K.L., Z.J., and F.B. conducted experiments and analyzed data. D. P., D.K. and A. M interpreted data and edited manuscript. R.W. and D.K. designed experiments and interpreted data. Y.Y-H. designed experiments, analyzed data, and wrote the manuscript. The authors read and approved the final manuscript.

Funding

MK was supported by National Natural Science Foundation of China [Award No. 81760542], Research Foundation of the Science and Technology Department of Guangxi Province, China [Award No. 2016GXNSFAA380252], Guangxi Medical University Training Program for Distinguished Young Scholars, and Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University. YY-H was supported by Discovery To Cure Ovarian Cancer Research Grant, Colleen's Dream Foundation Research Grant, and the Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program [Award No. W81XWH- 15-1-0221].

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files. The following is a list of the additional files.

Ethics approval and consent to participate

The clinical study protocol was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. The procedures are in accordance with the Helsinki Declaration of 1975. Written informed consent was obtained from all participants. Animal experiments were approved by the institutional committee at The First Affiliated Hospital of Guangxi Medical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹The First Affiliated Hospital of Guangxi Medical University, Nanning 530022, Guangxi, China. ²Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, USA. ³Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China. ⁴Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China. ⁵The first affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China. ⁶Sheng Jing Hospital of China Medical University, Shenyang 110004, Liaoning, China. ⁷Department of Pharmaceutical Sciences College of Pharmacy, University of Oklahoma, Oklahoma City, OK 73117, USA. ⁸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA. ⁹Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA. ¹⁰Yale Cancer Center, New Haven, CT 06510, USA.

Received: 30 June 2020 Accepted: 12 August 2020

Published online: 14 September 2020

References

- Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136:215–33.
- Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol*. 2014;15:509–24.
- Lauresergues D, Couzigou JM, Clemente HS, Martinez Y, Dunand C, Becard G, et al. Primary transcripts of microRNAs encode regulatory peptides. *Nature*. 2015;520:90–3.
- Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, McAnally JR, et al. A micropeptide encoded by a putative noncoding RNA regulates muscle performance. *Cell*. 2015;160:595–606.
- Nelson BR, Makarewich CA, Anderson DM, Winders BR, Troupes CD, Wu F, et al. A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. *Science*. 2016;351:271–5.
- Polycarpou-Schwarz M, Gross M, Mestdagh P, Schott J, Grund SE, Hildenbrand C, et al. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. *Oncogene*. 2018;37:4750–68.
- Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. *Nucleic Acids Res*. 2016;(44):D239–47.
- Qiao P, Li G, Bi W, Yang L, Yao L, Wu D: microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. *BMC Cancer*. 2015;15:469.
- Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. *Proc Natl Acad Sci U S A*. 2007;104:15472–7.
- Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. *Cell Signal*. 2015;27:443–52.
- Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Mol Cell*. 2007;26:745–52.
- Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. *Mol Cell*. 2007;26:731–43.
- Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. *Cell Cycle*. 2007;6:1586–93.
- Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. *Front Genet*. 2012;3:120.
- Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Investig New Drugs*. 2017;35:180–8.
- Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. *Lancet*. 2016;387:1012–24.
- Chou J, Lin YC, Kim J, You L, Xu Z, He B, et al. Nasopharyngeal carcinoma—review of the molecular mechanisms of tumorigenesis. *Head Neck*. 2008;30:946–63.
- Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomark Prev*. 2006;15:1765–77.
- Sun XS, Liu DH, Liu SL, Chen QY, Guo SS, Wen YF, et al. Patterns of failure and survival trends in 3,808 patients with stage II nasopharyngeal carcinoma diagnosed from 1990 to 2012: a large-scale retrospective cohort study. *Cancer Res Treat*. 2019;51(4):1449.
- Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. *Int J Radiat Oncol Biol Phys*. 2005;61:1107–16.
- Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. *Nat Protoc*. 2012;7:1755–64.
- Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. *Nat Protoc*. 2006;1:241–5.
- Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, et al. A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. *Mol Cancer*. 2019;18:131.
- el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. *Cell*. 1993;75:817–25.
- Bottlinger L, Oeljeklaus S, Guiard B, Rospert S, Warscheid B, Becker T. Mitochondrial heat shock protein (Hsp) 70 and Hsp10 cooperate in the formation of Hsp60 complexes. *J Biol Chem*. 2015;290:11611–22.
- Park SJ, Shin JH, Jeong JI, Song JH, Jo YK, Kim ES, et al. Down-regulation of mortalin exacerbates Abeta-mediated mitochondrial fragmentation and dysfunction. *J Biol Chem*. 2014;289:2195–204.
- Wadhwa R, Takano S, Kaur K, Aida S, Yaguchi T, Kaul Z, et al. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. *Biochem J*. 2005;391:185–90.
- Burbulla LF, Fitzgerald JC, Stegen K, Westermeier J, Thost AK, Kato H, et al. Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1. *Cell Death Dis*. 2014;5:e1180.
- Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. TP63 suppresses metastasis through coordinate regulation of dicer and miRNAs. *Nature*. 2010;467:986–90.
- Gayet B, Palazzo L, Fekete F, Paolaggi JA. Prospective study on the value of esophageal transluminal echography (echoendoscopy) in tumor pathology. *Pathol Biol (Paris)*. 1989;37:997–8.
- Mullany LK, Wong KK, Marciano DC, Katsonis P, King-Crane ER, Ren YA, et al. Specific TP53 mutants overrepresented in ovarian cancer impact CNV, TP53 activity, responses to Nutlin-3a, and cell survival. *Neoplasia*. 2015;17:789–803.
- Chatterjee K, Das P, Chattopadhyay NR, Mal S, Choudhuri T. The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies. *Heliyon*. 2019;5:e02624.
- McCormick TM, Canejo NH, Furtado YL, Silveira FA, de Lima RJ, Rosman AD, et al. Association between human papillomavirus and Epstein - Barr virus DNA and gene promoter methylation of RB1 and CDH1 in the cervical lesions: a transversal study. *Diagn Pathol*. 2015;10:59.
- Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mtHsp70/PBP74/Grp75: what, when, and where? *Cell Stress Chaperones*. 2002;7:309–16.
- Yang H, Zhou X, Liu X, Yang L, Chen Q, Zhao D, et al. Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin. *Biochem Biophys Res Commun*. 2011;410:114–20.
- Taurin S, Seyrantepe V, Orlov SN, Tremblay TL, Thibault P, Bennett MR, et al. Proteome analysis and functional expression identify mortalin as an antiapoptotic gene induced by elevation of [Na⁺]_i/[K⁺]_i ratio in cultured vascular smooth muscle cells. *Circ Res*. 2002;91:915–22.
- Kaula SC, Reddel RR, Sugiharac T, Mitsui Y, Wadhwa R. Inactivation of p53 and life span extension of human diploid fibroblasts by mot-2. *FEBS Lett*. 2000;474:159–64.
- Qu M, Zhou Z, Xu S, Chen C, Yu Z, Wang D. Mortalin overexpression attenuates beta-amyloid-induced neurotoxicity in SH-SY5Y cells. *Brain Res*. 2011;1368:336–45.
- Xu L, Voloboueva LA, Ouyang Y, Emery JF, Giffard RG. Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces

- oxidative stress, and protects from focal ischemia. *J Cereb Blood Flow Metab.* 2009;29:365–74.
40. Brunner M, Schneider HC, Lill R, Neupert W. Dissection of protein translocation across the mitochondrial outer and inner membranes. *Cold Spring Harb Symp Quant Biol.* 1995;60:619–27.
 41. Schneider HC, Berthold J, Bauer MF, Dietmeier K, Guiard B, Brunner M, et al. Mitochondrial Hsp70/MIM44 complex facilitates protein import. *Nature.* 1994;371:768–74.
 42. Marom M, Azem A, Mokranjac D. Understanding the molecular mechanism of protein translocation across the mitochondrial inner membrane: still a long way to go. *Biochim Biophys Acta.* 1808;2011:990–1001.
 43. Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. *Cell Stress Chaperones.* 2006;11:116–28.
 44. Voos W. Mitochondrial protein homeostasis: the cooperative roles of chaperones and proteases. *Res Microbiol.* 2009;160:718–25.
 45. Harner M, Neupert W, Deponite M. Lateral release of proteins from the TOM complex into the outer membrane of mitochondria. *EMBO J.* 2011;30:3232–41.
 46. Iosefson O, Azem A. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins—identification of additional interacting regions. *FEBS Lett.* 2010;584:1080–4.
 47. Ornatsky OI, Connor MK, Hood DA. Expression of stress proteins and mitochondrial chaperonins in chronically stimulated skeletal muscle. *Biochem J.* 1995;311(Pt 1):119–23.
 48. Takahashi M, Chesley A, Freyssenet D, Hood DA. Contractile activity-induced adaptations in the mitochondrial protein import system. *Am J Phys.* 1998; 274:C1380–7.
 49. Schwarzer C, Barnikol-Watanabe S, Thinnies FP, Hilschmann N. Voltage-dependent anion-selective channel (VDAC) interacts with the dynein light chain Tctex1 and the heat-shock protein PBP74. *Int J Biochem Cell Biol.* 2002;34:1059–70.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

